Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp)

  • Abad, Raquel
  • Garcia-Amil, Cristina
  • Navarro Rivas, Carmen
  • Martín, Elena
  • Martín-Díaz, Ariadna
  • Vazquez-Moreno, Julio Alberto
Studies of meningococcal genetic population structure, including the potential associations between surface proteins variants and clonal complexes, are important to understand how new protein MenB vaccines might impact in specific scenarios. With the aim to analyze the diversity of Spanish invasive MenB strains, and genetic variability of the fHbp vaccine antigen, all MenB isolates received at National Reference Laboratory (NRL) from 2015 to 2018 were molecularly characterized. Material and methods: 108, 103, 87 and 112 invasive MenB strains isolated during 2015-2018, respectively, were received at NRL. The strains were whole genome sequenced, and porA, fetA, MLST and fHbp variability was analyzed. Potential impact on MenB vaccines coverage was also assessed. Results: A total of 42, 38 and 3 different FHbp subfamily A, B and A/B hybrid peptides, respectively, were found. FHbp subfamily A peptides were harboured by most of the strains (65.9%), being the most prevalent peptide 45 which was associated with genosubtype 22,14 and cc213. FHbp subfamily B peptides were harboured by 32.4% of the strains, and 6 strains harbouring subfamily A/B hybrid peptides were also found. The 64.15% of the strains showed FHbp variants "exact-match" or "cross-reactive" to the FHbp variants included in rLP2086 vaccine according to hSBA assays in the rLP2086 clinical development, and 15.85% showed FHbp peptides defined as predictors of FHbp-coverage for 4CMenB vaccine by gMATS. Conclusions: Due to invasive meningococcal strains temporal variability (eg prevalence of the cc213 increased from 3.6% in 2007 to 33% in 2018) affecting to the presence and distribution of the vaccine antigens, continuous detailed meningococcal surveillance and monitoring of the vaccine antigens is needed to determine the degree and durability of coverage provided by these protein vaccine.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Identification of a New HIV-1 BC Intersubtype Circulating Recombinant Form (CRF108_BC) in Spain

  • Cañada, J.E.
  • Delgado, E.
  • Gil, H.
  • Sánchez, M.
  • Benito, S.
  • García-Bodas, E.
  • Gómez-González, C.
  • Canut-Blasco, A.
  • Portu-Zapirain, J.
  • Sáez de Adana, E.
  • De la Peña, M.
  • Ibarra, S.
  • Cilla, G.
  • Iribarren, J.A.
  • Martínez-Sapiña, A.
  • Thomson, M.M.
The extraordinary genetic variability of human immunodeficiency virus type 1 (HIV-1) group M has led to the identification of 10 subtypes, 102 circulating recombinant forms (CRFs) and numerous unique recombinant forms. Among CRFs, 11 derived from subtypes B and C have been identified in China, Brazil, and Italy. Here we identify a new HIV-1 CRF_BC in Northern Spain. Originally, a phylogenetic cluster of 15 viruses of subtype C in protease-reverse transcriptase was identified in an HIV-1 molecular surveillance study in Spain, most of them from individuals from the Basque Country and heterosexually transmitted. Analyses of near full-length genome sequences from six viruses from three cities revealed that they were BC recombinant with coincident mosaic structures different from known CRFs. This allowed the definition of a new HIV-1 CRF designated CRF108_BC, whose genome is predominantly of subtype C, with four short subtype B fragments. Phylogenetic analyses with database sequences supported a Brazilian ancestry of the parental subtype C strain. Coalescent Bayesian analyses estimated the most recent common ancestor of CRF108_BC in the city of Vitoria, Basque Country, around 2000. CRF108_BC is the first CRF_BC identified in Spain and the second in Europe, after CRF60_BC, both phylogenetically related to Brazilian subtype C strains.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío
  • Esperanza-Cebollada, Elena
  • Llop, Marta
  • Robledo, Cristina
  • Vicente-Garcés, Clara
  • Ortega Blanco, Margarita
Leucèmia limfoblàstica aguda infantil; Seqüenciació de nova generació, Leucemia linfoblástica aguda infantil; Secuenciación de nueva generación, Childhood acute lymphoblastic leukemia; Next-generation sequencing, The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice., This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío|||0000-0001-9781-4198
  • Esperanza-Cebollada, Elena|||0000-0001-5451-0370
  • Llop, Marta
  • Robledo, Cristina|||0000-0003-0445-3210
  • Vicente-Garcés, Clara|||0000-0002-2556-043X
  • Alonso, Javier|||0000-0002-6287-8391
  • Barragán, Eva
  • Fernández, Guerau
  • Hernández-Sánchez, Jesús M.
  • Martín-Izquierdo, Marta
  • Maynou, Joan
  • Minguela, Alfredo|||0000-0003-2472-5893
  • Montaño, Adrián|||0000-0002-3178-6726
  • Ortega, Margarita
  • Torrebadell, Montserrat
  • Cervera, José|||0000-0001-8252-1106
  • Sánchez, Joaquín
  • Jiménez-Velasco, Antonio|||0000-0001-6421-7872
  • Riesco, Susana
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Lassaletta, Álvaro|||0000-0003-2881-1473
  • Fernández, José María
  • Rives, Susana|||0000-0002-5658-1831
  • Dapena, José Luis|||0000-0002-6711-7479
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Camós, Mireia|||0000-0003-3658-7942
The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology's complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (Oncomine TM Childhood Cancer Research Assay; Archer ® FusionPlex ® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2 ®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors

  • González, Nuria|||0000-0002-0087-5144
  • McKee, Krisha
  • Lynch, Rebecca M.
  • Georgiev, Ivelin S.
  • Jimenez, Laura
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Yuste, Eloísa
  • Kwong, Peter D.
  • Mascola, John R.
  • Alcami, Jose|||0000-0003-0023-7377
Only a small fraction of HIV-1-infected patients develop broadly neutralizing antibodies (bNAbs), a process generally associated to chronic antigen stimulation. It has been described that rare aviremic HIV-1-infected patients can generate bNAbs but this issue remains controversial. To address this matter we have assessed bNAb responses in a large cohort of long-term non-progressors (LTNPs) with low or undetectable viremia. Samples from the LTNP cohort of the Spanish AIDS Research Network (87 elite and 42 viremic controllers) and a control population of 176 viremic typical-progressors (TPs) were screened for bNAbs using Env-recombinant viruses. bNAb specificities were studied by ELISA using mutated gp120, neutralization assays with mutated viruses, and peptide competition. Epitope specificities were also elucidated from the serum pattern of neutralization against a panel of diverse HIV-1 isolates. Broadly neutralizing sera were found among 9.3% LTNPs, both elite (7%) and viremic controllers (14%). Within the broadly neutralizing sera, CD4 binding site antibodies were detected by ELISA in 4/12 LTNPs (33%), and 16/33 of TPs (48%). Anti-MPER antibodies were detected in 6/12 LTNPs (50%) and 14/33 TPs (42%) whereas glycan-dependent HIV-1 bNAbs were more frequent in LTNPs (11/12, 92%) as compared to TPs (12/33, 36%). A good concordance between standard serum mapping and neutralization-based mapping was observed. LTNPs, both viremic and elite controllers, showed broad humoral immune responses against HIV-1, including activity against many major epitopes involved in bNAbs-mediated protection.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío
  • Esperanza-Cebollada, Elena
  • Llop, Marta
  • Robledo, Cristina
  • Vicente-Garcés, Clara
  • Ortega Blanco, Margarita
Leucèmia limfoblàstica aguda infantil; Seqüenciació de nova generació, Leucemia linfoblástica aguda infantil; Secuenciación de nueva generación, Childhood acute lymphoblastic leukemia; Next-generation sequencing, The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice., This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship).